The European Commission is considering emergency approvals for COVID-19 vaccines as a faster alternative to lengthy conditional approvals that have previously been used, reports Reuters.This potential change is due to the Commission being under pressure from slow approvals of vaccines leading to slower adoption of COVID-19 shots as the U.S and Great Britain The European Medicines Agency approved the vaccine Pfizer Inc (NYSE: PFE) / BioNTech SE (NASDAQ: BNTX) in late December 2020, weeks after receiving approval in the USA and the US. The shot by Johnson & Johnson (NYSE: JNJ) is likely to get EU approval on Jan. March 28th, the FDA approved the sting on March 28th Approved February An EU official said the emergency procedure was normally used at national level for terminally ill patients, the EU had instead chosen the longer conditional marketing authorization because vaccines 'we inject healthy people' and the risk was disproportionate to the EMA approved three vaccines including Pfizer / BioNTech, Oxford-AstraZeneca Plc (NYSE: AZN), and Moderna Inc (NASDAQ: MRNA) However, EU countries can also grant individual approval to other vaccinations.In addition to the sluggish acceptance, the block is also faced with delivery and distribution problems, which leads to the disintegration of Europe's uniform vaccination strategy.According to the WHO, only 55% of the EU population have a first shot of the Approved Vaccines Received Some Members Are Now Trying to Secure Coronavirus Vaccines Executives from Austria and Denmark will visit Israel this week to discuss future options for vaccine manufacturing and delivery Other countries like Slovakia and Hungary have turned to Russia and China Turned to take recordings not approved in Europe Slovakia's approval for the Sputnik V vaccine is based on Russia's studies and a comprehensive assessment of the vaccine by experts in the country in early February, Hungary began rolling out Sputnik V Hungary is also the first EU country to introduce China's Sinopharm vaccine that the EMA has not approved The breach of the EU's centralized strategy takes place amid development within the AstraZeneca vaccine bloc, France recommended the AstraZeneca shot to everyone People under the age of 75 (from an earlier age limit of 65), including those with pre-existing health problems, AstraZeneca-Oxford University or Pfizer / BioNTech have been effective in preventing COVID-19 infections, hospitalizations and deaths, according to a small study Price Action: MRNA Stocks are up 12% at USD 1485, AZN is up 07% at 4805 and PFE stocks are up 0. 8% at USD 3377 in the premarket on last check Wednesday JNJ stocks closed 02% lower at USD 15902 and BNTX fell at $ 104 98, Down 48% on Tuesday More Info From BenzingaClick Here For Option Trades From BenzingaEuropean Officials Seek AstraZeneca COVID-19 Shot Support: CNBCMerck Offers JNJ COVID-19 Vaccine Production, Biden Administration Says: Report © 2021 Benzingacom Benzinga Does Not Offer Investment Advice All Rights Reserved